ATHX
Price:
$0.1018
Market Cap:
$6.28M
Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is in Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy ...[Read more]
Industry
Biotechnology
IPO Date
2007-06-12
Stock Exchange
NASDAQ
Ticker
ATHX
According to Athersys, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.06. This represents a change of -87.97% compared to the average of -0.50 of the last 4 quarters.
The mean historical PE Ratio of Athersys, Inc. over the last ten years is -4.90. The current -0.06 PE Ratio has changed 22.42% with respect to the historical average. Over the past ten years (40 quarters), ATHX's PE Ratio was at its highest in in the June 2014 quarter at 51.10. The PE Ratio was at its lowest in in the June 2015 quarter at -24.21.
Average
-4.90
Median
-4.92
Minimum
-8.45
Maximum
-0.15
Discovering the peaks and valleys of Athersys, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 100.25%
Maximum Annual PE Ratio = -0.15
Minimum Annual Increase = -93.65%
Minimum Annual PE Ratio = -8.45
Year | PE Ratio | Change |
---|---|---|
2022 | -0.15 | -93.65% |
2021 | -2.32 | -44.27% |
2020 | -4.17 | -0.48% |
2019 | -4.19 | -48.35% |
2018 | -8.10 | 28.81% |
2017 | -6.29 | -25.56% |
2016 | -8.45 | 64.03% |
2015 | -5.15 | -6.43% |
2014 | -5.51 | 17.40% |
2013 | -4.69 | 100.25% |
The current PE Ratio of Athersys, Inc. (ATHX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-2.21
5-year avg
-3.78
10-year avg
-4.90
Athersys, Inc.’s PE Ratio is greater than LianBio (-0.39), greater than Eton Pharmaceuticals, Inc. (-17.69), greater than Galera Therapeutics, Inc. (-0.14), greater than Checkpoint Therapeutics, Inc. (-1.81), greater than YS Biopharma Co., Ltd. (-2.20), greater than Sonnet BioTherapeutics Holdings, Inc. (-0.55), greater than ZyVersa Therapeutics, Inc. (-0.10), greater than Allarity Therapeutics, Inc. (-0.19), greater than Kiromic BioPharma, Inc. (-0.14), greater than Avenue Therapeutics, Inc. (-0.31), greater than Hoth Therapeutics, Inc. (-0.98), greater than Revelation Biosciences, Inc. (-0.09), greater than NeuroBo Pharmaceuticals, Inc. (-0.73), greater than Virax Biolabs Group Limited (-1.34), greater than TransCode Therapeutics, Inc. (-0.10), greater than Fortress Biotech, Inc. (-0.71), greater than Akebia Therapeutics, Inc. (-7.00), greater than Trevena, Inc. (-0.09), greater than Reviva Pharmaceuticals Holdings, Inc. (-1.10), greater than Pyxis Oncology, Inc. (-3.58), greater than Zura Bio Limited (-9.00), less than eFFECTOR Therapeutics, Inc. (-0.00), less than Altamira Therapeutics Ltd. (-0.03), greater than Elevation Oncology, Inc. (-0.93),
Company | PE Ratio | Market cap |
---|---|---|
-0.39 | $34.47M | |
-17.69 | $118.59M | |
-0.14 | $4.08M | |
-1.81 | $93.07M | |
-2.20 | $192.09M | |
-0.55 | $4.53M | |
-0.10 | $2.70M | |
-0.19 | $7.01M | |
-0.14 | $3.14M | |
-0.31 | $4.05M | |
-0.98 | $7.32M | |
-0.09 | $1.43M | |
-0.73 | $29.70M | |
-1.34 | $15.24M | |
-0.10 | $4.56M | |
-0.71 | $40.38M | |
-7.00 | $283.89M | |
-0.09 | $3.40M | |
-1.10 | $44.68M | |
-3.58 | $206.30M | |
-9.00 | $230.86M | |
-0.00 | $188.18K | |
-0.03 | $2.04M | |
-0.93 | $36.94M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Athersys, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Athersys, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Athersys, Inc.'s PE Ratio?
How is the PE Ratio calculated for Athersys, Inc. (ATHX)?
What is the highest PE Ratio for Athersys, Inc. (ATHX)?
What is the 3-year average PE Ratio for Athersys, Inc. (ATHX)?
What is the 5-year average PE Ratio for Athersys, Inc. (ATHX)?
How does the current PE Ratio for Athersys, Inc. (ATHX) compare to its historical average?